GlobalResearch and clinical trials
Oral oveporexton increased wakefulness in narcolepsy type 1 in two phase 3 trials
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
A total of 273 people took part in two phase 3 trials. They were aged between 16 and 70. The drug was taken twice a day for 12 weeks. The time patients could stay awake increased by 14 to 20 minutes. Attacks of sudden muscle weakness fell by 79% to 89%. Frequent urination and temporary sleeplessness were common.
What does it mean for patients and families?
The drug mimics the brain signal that is missing in this disease. The trial lasted 12 weeks, so long-term data are limited. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
Scientific paper: Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials. The New England Journal of Medicine, 2026. DOI: 10.1056/NEJMoa2601598 · PubMed 42714024
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Narcolepsy type 1
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.